Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.

Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, Cuillerier E, Fautrel B, Michelet C, Morel J, Puéchal X, Wendling D, Lemann M, Ravaud P, Mariette X; RATIO group.

Ann Rheum Dis. 2011 Apr;70(4):616-23. doi: 10.1136/ard.2010.137422. Epub 2010 Dec 21.

PMID:
21177290
2.

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.

Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, Keystone E.

Ann Rheum Dis. 2011 Feb;70(2):266-71. doi: 10.1136/ard.2010.132134. Epub 2010 Nov 19. Review. Erratum in: Ann Rheum Dis. 2011 Mar;70(3):560.

PMID:
21097801
3.

A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.

Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, Listing J, Michaud K, Mikuls T, Shadick N, Solomon DH, Weinblatt ME, Wolfe F, Zink A.

Semin Arthritis Rheum. 2010 Aug;40(1):2-14.e1. doi: 10.1016/j.semarthrit.2010.03.003.

4.

Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs.

Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP.

Semin Arthritis Rheum. 2010 Jun;39(6):425-41. doi: 10.1016/j.semarthrit.2009.12.002. Epub 2010 Mar 11. Review.

PMID:
20223500
5.

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.

Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P.

CMAJ. 2009 Nov 24;181(11):787-96. doi: 10.1503/cmaj.091391. Epub 2009 Nov 2. Erratum in: CMAJ. 2010 May 18;182(8):806.

6.

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A; B S R B R Control Centre Consortium, Symmons DP; BSR Biologics Register.

Ann Rheum Dis. 2010 Mar;69(3):522-8. doi: 10.1136/ard.2009.118935. Epub 2009 Oct 22.

7.

Biologics for rheumatoid arthritis: an overview of Cochrane reviews.

Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007848. doi: 10.1002/14651858.CD007848.pub2. Review.

PMID:
19821440
8.

Confounder summary scores when comparing the effects of multiple drug exposures.

Cadarette SM, Gagne JJ, Solomon DH, Katz JN, Stürmer T.

Pharmacoepidemiol Drug Saf. 2010 Jan;19(1):2-9. doi: 10.1002/pds.1845.

9.

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X; Research Axed on Tolerance of Biotherapies Group.

Arthritis Rheum. 2009 Jul;60(7):1884-94. doi: 10.1002/art.24632. Erratum in: Arthritis Rheum. 2009 Aug;60(8):2540. Lorthololary, O [corrected to Lortholary, O].

10.

Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients.

Patkar NM, Curtis JR, Teng GG, Allison JJ, Saag M, Martin C, Saag KG.

J Clin Epidemiol. 2009 Mar;62(3):321-7, 327.e1-7. doi: 10.1016/j.jclinepi.2008.06.006. Epub 2008 Oct 1.

11.

Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study.

Ting G, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Young M, Avorn J, Solomon DH.

Arthritis Res Ther. 2008;10(4):R95. doi: 10.1186/ar2482. Epub 2008 Aug 21.

12.

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE; American College of Rheumatology.

Arthritis Rheum. 2008 Jun 15;59(6):762-84. doi: 10.1002/art.23721. No abstract available.

13.

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.

Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, Lin C, Cornet PL, Dougados M.

Ann Rheum Dis. 2008 Aug;67(8):1096-103. Epub 2007 Nov 29.

14.

Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists.

Curtis JR, Xi J, Patkar N, Xie A, Saag KG, Martin C.

Arthritis Rheum. 2007 Dec;56(12):4226-7. No abstract available.

15.

Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.

Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL; British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ; British Society for Rheumatology Biologics Register.

Arthritis Rheum. 2007 Sep;56(9):2896-904.

16.

Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.

Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG.

Arthritis Rheum. 2007 Apr;56(4):1125-33.

17.

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.

Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, van Vollenhoven RF, Klareskog L.

Ann Rheum Dis. 2007 Oct;66(10):1339-44. Epub 2007 Jan 29. Erratum in: Ann Rheum Dis. 2007 Nov;66(11):1548.

18.

Infections in patients with rheumatoid arthritis treated with biologic agents.

Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A.

Arthritis Rheum. 2005 Nov;52(11):3403-12.

19.
20.

Evaluating medication effects outside of clinical trials: new-user designs.

Ray WA.

Am J Epidemiol. 2003 Nov 1;158(9):915-20.

PMID:
14585769

Supplemental Content

Support Center